Related Experiment Videos
Successful tolerance induction to spiramycin in pregnancy
Eleonora Nucera1, Chiara Roncallo, Lucia Masini
1Department of Allergology, Università Cattolica del Sacro Cuore, Policlinico A. Gemelli, Rome, Italy.
Scandinavian Journal of Infectious Diseases
|August 28, 2002
Summary
Two pregnant patients with toxoplasmosis experienced a rash during spiramycin treatment. A tolerance induction protocol allowed them to safely continue spiramycin therapy throughout pregnancy without adverse effects.
Area of Science:
- Obstetrics and Gynecology
- Infectious Diseases
- Dermatology
Background:
- Toxoplasmosis is a parasitic infection that can pose risks during pregnancy.
- Spiramycin is a commonly prescribed antibiotic for treating toxoplasmosis in pregnant individuals.
Observation:
- Two pregnant patients undergoing spiramycin therapy for toxoplasmosis presented with an erythematous, maculopapular rash.
- The rash resolved upon cessation of spiramycin treatment, suggesting a drug-induced reaction.
Findings:
- A tolerance induction protocol enabled both patients to resume and complete spiramycin therapy.
- Successful desensitization allowed for continued treatment until the end of gestation without recurrence of side-effects.
Implications:
- This case series suggests a viable strategy for managing spiramycin-induced rash in pregnant patients.
- Tolerance induction protocols may allow pregnant women to benefit from essential antimicrobial therapy despite initial adverse reactions.
- Further research into desensitization protocols for spiramycin is warranted to ensure safe and effective toxoplasmosis treatment in pregnancy.